BEACOPP regimen

WikiDoc Resources for BEACOPP regimen
Articles
Most recent articles on BEACOPP regimen Most cited articles on BEACOPP regimen Review articles on BEACOPP regimen Articles on BEACOPP regimen in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on BEACOPP regimen Images of BEACOPP regimen Photos of BEACOPP regimen Podcasts & MP3s on BEACOPP regimen Videos on BEACOPP regimen
Evidence Based Medicine
Cochrane Collaboration on BEACOPP regimen Bandolier on BEACOPP regimen TRIP on BEACOPP regimen
Clinical Trials
Ongoing Trials on BEACOPP regimen at Clinical Trials.gov Trial results on BEACOPP regimen Clinical Trials on BEACOPP regimen at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on BEACOPP regimen NICE Guidance on BEACOPP regimen NHS PRODIGY Guidance FDA on BEACOPP regimen CDC on BEACOPP regimen
Books
Books on BEACOPP regimen
News
BEACOPP regimen in the news Be alerted to news on BEACOPP regimen News trends on BEACOPP regimen
Commentary
Blogs on BEACOPP regimen
Definitions
Definitions of BEACOPP regimen
Patient Resources / Community
Patient resources on BEACOPP regimen Discussion groups on BEACOPP regimen Patient Handouts on BEACOPP regimen Directions to Hospitals Treating BEACOPP regimen Risk calculators and risk factors for BEACOPP regimen
Healthcare Provider Resources
Symptoms of BEACOPP regimen Causes & Risk Factors for BEACOPP regimen Diagnostic studies for BEACOPP regimen Treatment of BEACOPP regimen
Continuing Medical Education (CME)
CME Programs on BEACOPP regimen
International
BEACOPP regimen en Espanol BEACOPP regimen en Francais
Business
BEACOPP regimen in the Marketplace Patents on BEACOPP regimen
Experimental / Informatics
List of terms related to BEACOPP regimen

Overview

BEACOPP is a chemotherapy regimen for treatment of Hodgkin's lymphoma in Stages > II. Patients typically receive treatment in cycles of 21 days with no drugs given on days 16-21. There also exists a more intensive regimen with cycles of 14 days. Usually a therapy consists of eight, sometimes six cycles. In some countries BEACOPP still is experimental, in others (eg. Germany and Austria) it is a standard therapy. The reason that the United States physicians still use ABVD (or Stanford V) is that they think that BEACOPP induces more secondary neoplasias as leukemias, etc. However, this (after 10 years of experience) is not the case. BEACOPP delivers approximately 10-15% more cures in advanced Hodgkins disease (IIB+risk factors or stages III and IV). BEACOPP is more expensive as it requires G-CSF support. However, it is well worth it because of the higher cure rates.

m² = body surface

i.v.=intravenous

BEACOPP basic:

(C)yclophosphamide	650 mg/m²	(i.v.)	day 1
(A)driamycin	25 mg/m²	i.v.	day 1
(E)toposide	100 mg/m²	i.v.	day 1-3
Vincristin(=(O)ncovin)	1,4 mg/m² (max 2 mg)	i.v.	day 8
(B)leomycin	10 mg/m²	i.v.	day 8
(P)rocarbazine	100 mg/m²	orally	day 1-7
(P)rednisone	40 mg/m²	orally	day 1-14

BEACOPP escalated:

Cyclophosphamide	1250 mg/m² KO/day	i.v.	day 1
Adriamycin	35 mg/m²	i.v.	day 1
Etoposide	200 mg/m²	i.v.	day 1-3
Vincristine	1,4 mg/m² (max 2 mg)	i.v.	day 8
Bleomycin	10 mg/m²	i.v.	day 8
Procarbazine	100 mg/m²	orally	day 1-7
Prednisone	40 mg/m²	orally	day 1-14

See also

• Stanford V
• ABVD